48,180 results match your criteria Renal Cell Carcinoma


Liver metastasis and Heng risk are prognostic factors in patients with non-nephrectomized synchronous metastatic renal cell carcinoma treated with systemic therapy.

PLoS One 2019 20;14(2):e0211105. Epub 2019 Feb 20.

Department of Urology, Center for Prostate Cancer, National Cancer Center, Goyang, Korea.

Objective: This study aimed to determine the prognostic factors of progression-free survival (PFS) and overall survival (OS) in non-nephrectomized patients with synchronous metastatic renal cell carcinoma (mRCC) receiving first-line vascular endothelial growth factor (VEGF)-targeted therapy or immunotherapy.

Methods: Of 70 patients, 57 (81.4%) were treated with targeted therapy, including 5 (7. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211105PLOS
February 2019

A higher circulating concentration of 25-hydroxyvitamin-D decreases the risk of renal cell carcinoma: a case-control study.

Int Braz J Urol 2019 Feb 10;45. Epub 2019 Feb 10.

Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, P.R. China.

Objective: To investigate the relationship between vitamin D status, using circulating 25-hydroxyvitamin D [25 (OH) D], and renal cell carcinoma (RCC) risk in a case-control study, because the association between the two is unclear in China.

Materials And Methods: A total of 135 incident RCC cases were matched with 135 controls by age and sex. The blood samples were collected on the first day of hospitalization before surgery to measure plasma 25 (OH) D. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/S1677-5538.IBJU.2018.0186DOI Listing
February 2019

Fumarate hydratase deficient renal cell carcinoma: Chromosomal numerical aberration analysis of 12 cases.

Ann Diagn Pathol 2019 Feb 10;39:63-68. Epub 2019 Feb 10.

Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, University Hospital Plzen, Pilsen, Czech Republic. Electronic address:

Hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma (HLRCC)/fumarate hydratase deficient renal cell carcinoma (FHRCC) is defined by molecular genetic changes (mutation/LOH in fumarate hydratase (FH) gene). We investigated chromosomal numerical aberration pattern (CNV) in FHRCC/HLRCC using array comparative genomic hybridization analysis and low pass whole genome sequencing. Genetic analysis was successfully completed in 12 tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anndiagpath.2019.02.008DOI Listing
February 2019

Symptomatic radiation necrosis in brain metastasis patients treated with stereotactic radiosurgery and immunotherapy.

Clin Neurol Neurosurg 2019 Feb 11;179:14-18. Epub 2019 Feb 11.

Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, United States. Electronic address:

Objectives: The association of symptomatic radiation necrosis (RN) with stereotactic radiosurgery (SRS) and immune checkpoint inhibitors (ICIs) in brain metastases patients has been incompletely explored. We aim to discuss the incidence, risk factors, and prognosis of symptomatic RN in patients treated with these modalities.

Patients And Methods: We retrospectively evaluated the incidence of symptomatic RN among all patients with brain metastases treated with both SRS and an ICI at a single academic center. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clineuro.2019.02.010DOI Listing
February 2019

GRK5 promotes tumor progression in renal cell carcinoma.

Neoplasma 2019 Feb 6;66(2). Epub 2019 Feb 6.

Department of Urology, Changzheng Hospital, The Second Military Medical University, Shanghai, China.

GRK5 is a multifunctional protein that is able to move within the cell in response to various stimuli to regulate key intracellular signaling from receptor activation, on plasmamembrane, to gene transcription, in the nucleus. Thus, GRK5 is involved in the development and progression of several pathological conditions including cancer. Here, we report an important tumor-promoting role for GRK5 in renal cell carcinoma (RCC). Read More

View Article

Download full-text PDF

Source
http://www.elis.sk/index.php?page=shop.product_details&f
Publisher Site
http://dx.doi.org/10.4149/neo_2018_180621N409DOI Listing
February 2019
1 Read

Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors.

Drugs Aging 2019 Feb 20. Epub 2019 Feb 20.

Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope Dr, Suite 2161, Salt Lake City, UT, 84112, USA.

Given the underrepresentation of older patients in registration trials for metastatic renal cell carcinoma (mRCC), data to support the use of any particular systemic therapy over others, based on age, is limited. This is further complicated by clinical trials not commonly reporting adverse events by age. Thus, recommendations on treatment of older patients with mRCC are generally extrapolated from data on younger patients enrolled in these trials, which may not be ideal as many older patients are frail, have age-related organ dysfunction, or have multiple medical co-morbidities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40266-019-00644-1DOI Listing
February 2019

Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study.

Med Oncol 2019 Feb 19;36(3):29. Epub 2019 Feb 19.

Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

The introduction of targeted therapy for the treatment of advanced renal cell carcinoma (RCC) has improved the outcome of these patients in the last decade. However, many patients still relapse. The aim of this consensus study was to establish common recommendations about the best treatment options in patients with RCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12032-019-1251-7DOI Listing
February 2019

The repair using a fibular graft of cervical vertebral collapse due to renal cell carcinoma: Late results with a case report.

J Craniovertebr Junction Spine 2018 Oct-Dec;9(4):267-270

Department of Pathology, Research and Training Hospital, Recep Tayyip Erdogan University, Rize, Turkey.

The most common cause of spinal tumors is metastases, but the cervical vertebra is the least common region of spinal metastasis, and relatively, little is published about surgery in metastasis to the cervical vertebra. While spinal metastasis is most often caused by neoplasms originating from the lung, breast, and prostate, renal cell carcinoma (RCC) metastasis is very rare. A 47-year-old patient introduced here presented with severe pain spontaneously on his neck and in his arm. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jcvjs.JCVJS_32_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364372PMC
February 2019

Apelin and apelin receptor expression in renal cell carcinoma.

Br J Cancer 2019 Feb 20. Epub 2019 Feb 20.

Department of Urology, University Hospital Bonn, Sigmund-Freud-Strasse 25, 53105, Bonn, Germany.

Background: The APLNR (apelin receptor) has been shown to be an essential gene for cancer immunotherapy, with deficiency in APLNR leading to immunotherapy failure. The aim of this study is to investigate the expression of APLN (apelin) and APLNR in patients with renal cell carcinoma (RCC), and its association with clinicopathological parameters and survival.

Methods: Three well-characterised patient cohorts with RCC were used: Study cohort 1 (clear-cell RCC; APLN/APLNR mRNA expression; n = 166); TCGA validation cohort (clear-cell RCC; APLN/APLNR mRNA expression; n = 481); Study cohort 2 (all RCC subtypes; APLNR protein expression/immunohistochemistry; n = 300). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0396-7DOI Listing
February 2019

Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions.

Expert Rev Endocrinol Metab 2012 Sep;7(5):541-554

f Massachusetts General Hospital, Boston, MA, USA.

Approximately 90% of thyroid cancers are differentiated (DTCs) and have papillary, follicular or Hürthle cell morphology. Although treatment with surgery and radioactive iodine (I-131; RAI), as appropriate, is associated with significant cure rates and survival benefits, clonal disease progression with development of refractoriness to RAI poses a major therapeutic challenge in about 15% of patients. Traditional chemotherapeutic agents are relatively ineffective and are associated with significant toxicities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/eem.12.36DOI Listing
September 2012

The Enigmatic Protein Kinase C-eta.

Authors:
Alakananda Basu

Cancers (Basel) 2019 Feb 13;11(2). Epub 2019 Feb 13.

Department of Microbiology, Immunology & Genetics, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.

Protein kinase C (PKC), a multi-gene family, plays critical roles in signal transduction and cell regulation. Protein kinase C-eta (PKCη) is a unique member of the PKC family since its regulation is distinct from other PKC isozymes. PKCη was shown to regulate cell proliferation, differentiation and cell death. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11020214DOI Listing
February 2019

Leukocyte⁻Cancer Cell Fusion-Genesis of a Deadly Journey.

Cells 2019 Feb 18;8(2). Epub 2019 Feb 18.

Department of Dermatology and The Yale Cancer Center, Yale School of Medicine, New Haven, CT 06520-8059, USA.

According to estimates from the International Agency for Research on Cancer, by the year 2030 there will be 22 million new cancer cases and 13 million deaths per year. The main cause of cancer mortality is not the primary tumor itself but metastasis to distant organs and tissues, yet the mechanisms of this process remain poorly understood. Leukocyte⁻cancer cell fusion and hybrid formation as an initiator of metastasis was proposed more than a century ago by the German pathologist Prof. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cells8020170DOI Listing
February 2019

Loss of MYBBP1A Induces Cancer Stem Cell Activity in Renal Cancer.

Cancers (Basel) 2019 Feb 18;11(2). Epub 2019 Feb 18.

Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío (HUVR), Universidad de Sevilla, Consejo Superior de Investigaciones Científicas, 41013 Seville, Spain.

Tumors are cellular ecosystems where different populations and subpopulations of cells coexist. Among these cells, cancer stem cells (CSCs) are considered to be the origin of the tumor mass, being involved in metastasis and in the resistance to conventional therapies. Furthermore, tumor cells have an enormous plasticity and a phenomenon of de-differentiation of mature tumor cells to CSCs may occur. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11020235DOI Listing
February 2019

Acquired Lipodystrophy Associated with Nivolumab in a Patient with Advanced Renal Cell Carcinoma.

J Clin Endocrinol Metab 2019 Feb 19. Epub 2019 Feb 19.

Department of Endocrinology and Metabolism, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (USP), São Paulo, Brazil.

Context: Lipodystrophy syndromes are rare disorders characterized by the selective loss of adipose tissue. We aimed to report the first case of acquired generalized lipodystrophy possibly associated with nivolumab.

Case Description: A woman was referred to our Endocrinology Department for uncontrolled diabetes mellitus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2018-02221DOI Listing
February 2019

Long-term Survival of Patient with Ampulla of Vater Metastasis of Renal Cell Carcinoma.

Prague Med Rep 2018 ;119(4):165-169

Department of Surgery, Lithuanian University of Health Sciences, Kaunas, Lithuania.

Ampulla of Vater metastases from renal cell carcinoma are rare. The time between detection of the primary tumour and its metastasis may extend to years. Management should be aggressive, since the prognosis of renal cell carcinoma is unpredictable and curative surgery of metastases may extend patient survival and even lead to definite cure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14712/23362936.2019.4DOI Listing
January 2018

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

N Engl J Med 2019 02 16. Epub 2019 Feb 16.

From Memorial Sloan Kettering Cancer Center (R.J.M.) and Pfizer (S.H.), New York; Private Medical Institution Euromedservice (K.P.) and Nonstate Health Institution Road Clinical Hospital-Russian Railways (A.V.), St. Petersburg, and the Moscow Scientific Research Oncology Institute, Moscow (B.A.) - all in Russia; the Netherlands Cancer Institute, Amsterdam (J.H.); the Cleveland Clinic, Cleveland (B.R.); Institut Gustave Roussy, Villejuif (L.A.), and Centre Léon Bérard, University of Lyon, Lyon (S.N.) - both in France; the University of Texas M.D. Anderson Cancer Center, Houston (M.T.C.); University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow (B.V.), and Royal Marsden NHS Foundation Trust, London (J.L.) - both in the United Kingdom; British Columbia Cancer Agency, Vancouver (C.K.), and Lady Davis Institute and Jewish General Hospital, McGill University, Montreal (W.H.M.) - both in Canada; Osaka University Hospital, Osaka, Japan (M.U.); University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea (J.L.L.); Macquarie University, Sydney (H.G.); Department of Medicine I, Clinical Division of Oncology and Comprehensive Cancer Center, Medical University of Vienna, Vienna (M.S.); Georgetown Lombardi Comprehensive Cancer Center, Washington, DC (M.B.A.); Department of Urology, University of Tübingen, Tübingen, Germany (J.B.); Pfizer, Cambridge (J.W., A.C.), and the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, and Brigham and Women's Hospital, Boston (T.K.C.) - both in Massachusetts; Pfizer (M.M., A.P.) and Pfizer Italia (C.F.), Milan; Pfizer, San Diego, CA (P.B.R.); and Pfizer, Groton, CT (B.H.).

Background: In a single-group, phase 1b trial, avelumab plus axitinib resulted in objective responses in patients with advanced renal-cell carcinoma. This phase 3 trial involving previously untreated patients with advanced renal-cell carcinoma compared avelumab plus axitinib with the standard-of-care sunitinib.

Methods: We randomly assigned patients in a 1:1 ratio to receive avelumab (10 mg per kilogram of body weight) intravenously every 2 weeks plus axitinib (5 mg) orally twice daily or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1816047DOI Listing
February 2019

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

N Engl J Med 2019 02 16. Epub 2019 Feb 16.

From the Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Dnipropetrovsk Medical Academy of Ministry of Health of Ukraine (V.S.) and Dnipropetrovsk Medical Academy (I.B.), Dnipro, Sumy State University, Sumy Regional Oncology Center, Sumy (I.V.), and Ivano-Frankivsk National Medical University, Ivano-Frankivsk (A.K.) - all in Ukraine; the Russian Scientific Center of Roentgen Radiology (R.G.), Central Clinical Hospital with Outpatient Clinic (D.N.), and Hertzen Moscow Cancer Research Institute (B.A.), Moscow; the Christie NHS Foundation Trust, Manchester (R.H.), and Barts Health and the Royal Free NHS Trusts, Barts Cancer Institute, and Queen Mary University of London, London (T.P.) - all in the United Kingdom; Centre Hospitalier Universitaire (CHU) de Québec and Université Laval, Quebec, QC (F.P.), and CHU de Montréal, Montreal (D.S.) - both in Canada; Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (S.J.A.); Centre Antoine Lacassagne, Université Côte d'Azur, Nice (D.B.), and Hôpitaux Universitaires de Lyon, Lyon (S. Tartas) - both in France; Military Institute of Medicine, Warsaw, Poland (C.S.); Rocky Mountain Cancer Center, Colorado Springs, CO (M.M.); Adelaide and Meath Hospital and University College Dublin, Dublin (R.S.M.); the Department of Urology, Eberhard-Karls University Tübingen, Tübingen, Germany (J.B.); Taipei Veterans General Hospital, Taipei, Taiwan (Y.-H.C.); Osaka City University Hospital, Osaka, Japan (S. Tamada); MSD China, Beijing (Q.S.); Merck, Kenilworth, NJ (R.F.P., M.C.); and Georgetown Lombardi Comprehensive Cancer Center, Washington, DC (M.B.A.).

Background: The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether pembrolizumab plus axitinib would result in better outcomes than sunitinib in such patients was unclear.

Methods: In an open-label, phase 3 trial, we randomly assigned 861 patients with previously untreated advanced clear-cell renal-cell carcinoma to receive pembrolizumab (200 mg) intravenously once every 3 weeks plus axitinib (5 mg) orally twice daily (432 patients) or sunitinib (50 mg) orally once daily for the first 4 weeks of each 6-week cycle (429 patients). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1816714DOI Listing
February 2019

Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma.

Authors:
Bernard Escudier

N Engl J Med 2019 02 16. Epub 2019 Feb 16.

From the Gustave Roussy Cancer Campus, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe1900887DOI Listing
February 2019

Deep learning and radiomics: the utility of Google TensorFlow™ Inception in classifying clear cell renal cell carcinoma and oncocytoma on multiphasic CT.

Abdom Radiol (NY) 2019 Feb 18. Epub 2019 Feb 18.

Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Ronald Reagan-UCLA Medical Center, 757 Westwood Plaza, RRUMC 1621H, Box 957437, Los Angeles, CA, 90095, USA.

Purpose: Currently, all solid enhancing renal masses without microscopic fat are considered malignant until proven otherwise and there is substantial overlap in the imaging findings of benign and malignant renal masses, particularly between clear cell RCC (ccRCC) and benign oncocytoma (ONC). Radiomics has attracted increased attention for its utility in pre-operative work-up on routine clinical images. Radiomics based approaches have converted medical images into mineable data and identified prognostic imaging signatures that machine learning algorithms can use to construct predictive models by learning the decision boundaries of the underlying data distribution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00261-019-01929-0DOI Listing
February 2019

A comparative analysis of various surgical approaches of nephron-sparing surgery and correlation of histopathological grade with RENAL nephrometry score in renal cell carcinoma.

J Minim Access Surg 2019 Feb 18. Epub 2019 Feb 18.

Department of Urology, All India Institute of Medical Sciences, New Delhi, India.

Background: Nephron-sparing surgery (NSS) is the standard of care for small renal masses whenever feasible. This study aims to evaluate the perioperative outcomes of NSS performed by open (open partial nephrectomy [OPN]) or laparoscopic (laparoscopic PN [LPN]) or robotic (robotic PN [RPN]) approach over the past 6 years and to study the correlation of histopathological grade of renal cell carcinoma with the RENAL score.

Materials And Methods: A retrospective analysis of prospectively collected data of all patients who underwent NSS was done. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jmas.JMAS_208_18DOI Listing
February 2019

Long-Term Outcome of Zero-Ischemia Partial Nephrectomy for the Treatment of Multifocal Renal Cell Carcinoma in Renal Transplant Allograft: A Case Report.

Exp Clin Transplant 2019 Jan;17(Suppl 1):145-147

From the Department of Urology and Kidney Transplantation, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Multifocal synchronous renal cell carcinoma in the functioning allograft is a rare disease; there is no consensus regarding its treatment, and few cases have been reported. In isolated masses, some authorities advocate graft nephrectomy, and some recommend partial nephrectomy. To our knowledge, we describe the first experience of nephron-sparing surgery in multifocal synchronous renal cell carcinoma in an allograft with its long-term outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6002/ect.MESOT2018.P13DOI Listing
January 2019

Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma.

Urol Oncol 2019 Feb 15. Epub 2019 Feb 15.

Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

Purpose: Micropapillary variant upper tract urothelial cancer (MP-UTUC) is a rare malignancy with little known regarding its clinical course and/or optimal treatment. In this case series, we describe patient characteristics, surgical treatment, oncologic outcomes, and response to perioperative chemotherapy.

Materials And Methods: We conducted a review to identify patients with MP-UTUC treated at our center between January 1994 and October 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2019.01.026DOI Listing
February 2019

Anti-silencing function 1B histone chaperone promotes cell proliferation and migration via activation of the AKT pathway in clear cell renal cell carcinoma.

Biochem Biophys Res Commun 2019 Feb 15. Epub 2019 Feb 15.

Department of Organ Transplantation, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, 430060, China.

Clear cell renal cell carcinoma (ccRCC) is one of the most common malignancies. Anti-silencing function 1B histone chaperone (ASF1B) has been reported to be involved in various diseases. However, its role in ccRCC is largely unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2019.02.060DOI Listing
February 2019

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.

J Immunother Cancer 2019 Feb 18;7(1):49. Epub 2019 Feb 18.

Beth Israel Deaconess Medical Center, Boston, MA, USA.

Background: Metastatic melanoma (mM) and renal cell carcinoma (mRCC) are often treated with anti-PD-1 based therapy, however not all patients respond and further therapies are needed. High dose interleukin-2 (HD IL-2) can lead to durable responses in a subset of mM and mRCC patients. The efficacy and toxicity of HD IL-2 therapy following anti-PD-1 or anti-PD-L1 therapy have not yet been explored. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0522-3DOI Listing
February 2019

loss sensitizes cells to PI3Kβ and AKT inhibition.

Oncotarget 2019 Jan 18;10(6):647-659. Epub 2019 Jan 18.

Vanderbilt-Ingram Cancer Center, Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville 37232, TN, USA.

Upregulation of the PI3K pathway has been implicated in the initiation and progression of several types of cancer, including renal cell carcinoma (RCC). Although several targeted therapies have been developed for RCC, durable and complete responses are exceptional. Thus, advanced RCC remains a lethal disease, underscoring the need of robust biomarker-based strategies to treat RCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26567DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363018PMC
January 2019

Synchronous bilateral renal cell carcinomas in "Asynchrony of metabolism".

World J Nucl Med 2019 Jan-Mar;18(1):63-65

Department of Nuclear Medicine and PET/CT, Basavatarakam Indo-American Cancer Hospital, Hyderabad, Telangana, India.

Here, we present a case of bilateral synchronous renal cell carcinoma in a 52-year-old male patient, who underwent fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) scan followed by surgical removal of both tumors. On PET scan, left renal mass showed intense FDG uptake while uptake in the right renal mass was minimal. Histopathologically, both tumors were conventional clear cell carcinoma (Fuhrman Grade III). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/wjnm.WJNM_5_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357702PMC
February 2019

The coexistence of a Wilms' tumor and renal cell carcinoma in children: a case report and review of the literature.

Onco Targets Ther 2019 30;12:953-958. Epub 2019 Jan 30.

Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China,

A combination of a Wilms' tumor (WT) and renal cell carcinoma (RCC) is an extremely rare pediatric renal neoplasm. Its prognosis and clinicopathological features remain unclarified. Herein, we describe a case of the coexistence of a WT and an RCC in a male child aged 5 years and 10 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S186102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361228PMC
January 2019

Radiotherapy in advanced glottic laryngeal carcinoma in a patient with Wegener's granulomatosis: how much radiation dose is needed?

Onco Targets Ther 2019 23;12:753-757. Epub 2019 Jan 23.

Radiation Oncology Unit, San Giuseppe Moscati Hospital, Taranto, Italy,

Wegener's granulomatosis (WG) is an autoimmune disorder characterized by necrotizing granulomas involving mainly the upper-lower respiratory and renal tracts, albeit a potentially life-threatening involvement of other body parts is not rare. Furthermore, there are several reports accounting for an increased risk of solid malignancies due to the autoimmune disease per se, or the immunosuppressive therapies. Among treatments, radiotherapy could be a therapeutic option as proven by its use in typical WG lesions such as solitary granulomas or subglottic stenosis, successfully treated with low radiation dose. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S182011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352862PMC
January 2019

Low Expression of ATM Indicates a Poor Prognosis in Clear Cell Renal Cell Carcinoma.

Clin Genitourin Cancer 2019 Jan 10. Epub 2019 Jan 10.

Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan Province, PR China. Electronic address:

Introduction: The study was carried out to examine the expression of ataxia telangiectasia mutant (ATM) of clear cell renal cell carcinoma (ccRCC), and to explore the relationship between the expression of ATM and the clinicopathologic parameters and prognosis of ccRCC.

Materials And Methods: Clinicopathologic data of the patients with ccRCC were collected from January 2011 to August 2015 in Xiangya Hospital, Central South University. The immunohistochemical method was used to detect the expression of ATM in ccRCC and adjacent tissues. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673193001
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2019.01.003DOI Listing
January 2019
1 Read

TOX3 Inhibits Cancer Cell Migration and Invasion via Transcriptional Regulation of SNAI1 and SNAI2 in Clear Cell Renal Cell Carcinoma.

Cancer Lett 2019 Feb 14. Epub 2019 Feb 14.

Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, 321 Zhongshan Road, Nanjing, 210008, Jiangsu, PR China. Electronic address:

Studies on the mechanism of clear cell renal cell carcinoma (ccRCC) progression are lacking. In this study, TOX3 was identified as a novel cancer suppressor gene in ccRCC. Hypermethylation of CpG probes in the promoter region was associated with the functional loss of TOX3 in ccRCC cancer tissues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2019.02.020DOI Listing
February 2019
1 Read

Essential Research Priorities in Renal Cancer: A Modified Delphi Consensus Statement.

Eur Urol Focus 2019 Feb 13. Epub 2019 Feb 13.

Department of Surgery, University of Cambridge, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK. Electronic address:

Background: Identification of clear and focused research priorities is crucial to drive research forward.

Objective: To identify research priorities in renal cell carcinoma (RCC) through a multidisciplinary collaboration between clinicians, researchers, and patients.

Design, Setting, And Participants: In phase I, 44 RCC experts provided 24 literature reviews within their field, summarising research gaps (RGs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2019.01.014DOI Listing
February 2019
1 Read

Impact of Disagreement Between Two Risk Group Models on Prognosis in Patients With Metastatic Renal-Cell Carcinoma.

Clin Genitourin Cancer 2019 Jan 17. Epub 2019 Jan 17.

Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Purpose: To investigate the impact of the risk group disagreement between the Memorial Sloan Kettering Cancer Center (MSKCC) and the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) models on prognosis.

Patients And Methods: We retrospectively evaluated 176 patients with metastatic renal-cell carcinoma who were treated with tyrosine kinase inhibitors as first-line therapy in 5 hospitals between October 2008 and August 2018. The risk group classification differences between the MSKCC and the IMDC models were evaluated using criteria of agreement (identical risk group in both the MSKCC and IMDC models) and disagreement (not identical risk group in both the MSKCC and IMDC models). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.01.006DOI Listing
January 2019
1 Read

ERK Inhibitor Enhances Everolimus Efficacy through the Attenuation of dNTP Pools in Renal Cell Carcinoma.

Mol Ther Nucleic Acids 2019 Jan 10;14:550-561. Epub 2019 Jan 10.

Department of Urology and Andrology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200011, China. Electronic address:

The clinical efficiency of everolimus, an mammalian target of rapamycin (mTOR) inhibitor, is palliative as sequential or second-line therapy for renal cell carcinoma (RCC). However, the limited response of everolimus in RCC remains uncertain. In the present study, everolimus-resistant RCC models were established to understand the mechanisms and to seek combination approaches. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.omtn.2019.01.001DOI Listing
January 2019
1 Read

Association Between Activation of the Programmed Cell Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Pathway and Pain in Patients with Cancer.

Med Sci Monit 2019 Feb 16;25:1275-1282. Epub 2019 Feb 16.

Department of Palliative Care, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland).

BACKGROUND The aim of this study was to investigate the clinical correlation between sPD-1 (soluble programmed cell death-1) and PD-1 (programmed cell death-1) expression and cancer pain. MATERIAL AND METHODS sPD-1 content in peripheral blood was determined by enzyme-linked immunosorbent assay (ELISA). T cell surface-positive rate was determined by flow cytometry, and the correlation of clinical characteristics of patients with cancer pain was analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/MSM.912632DOI Listing
February 2019
1 Read

Long noncoding RNA EGFR-AS1 promotes cell growth and metastasis via affecting HuR mediated mRNA stability of EGFR in renal cancer.

Cell Death Dis 2019 Feb 15;10(3):154. Epub 2019 Feb 15.

Department of Urology, Changzheng Hospital, Second Military Medical University, 415 Fengyang Road, 200003, Shanghai, China.

Long noncoding RNAs (lncRNAs) are implicated in renal cell carcinoma (RCC), but remain largely unclear. Using publicly available transcriptome sequencing data from renal cancer (n = 703) and integrating bioinformatics analyses, we screened and identified a valuable lncRNA, EGFR-AS1. In our validation cohort (n = 204), EGFR-AS1 was significantly upregulated in RCC tissues (P < 0. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41419-019-1331-9
Publisher Site
http://dx.doi.org/10.1038/s41419-019-1331-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377662PMC
February 2019
2 Reads
5.014 Impact Factor

LXRα promotes cell metastasis by regulating the NLRP3 inflammasome in renal cell carcinoma.

Cell Death Dis 2019 Feb 15;10(3):159. Epub 2019 Feb 15.

Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

Notwithstanding the researches on biomarkers and targeted therapies in renal cell carcinomas (RCC) have made progress in the last decades, the application of the biomarkers and targeted therapy agents for RCC in clinic are restricted because of their limitation or side effects. Liver X receptors (LXRs) and the NLRP3 inflammasome have been the research hotspots in recent years. In our study, we integrated bioinformatics analysis, molecular biology experiments and biological function experiments to study the roles of LXRα and the NLRP3 inflammasome in RCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41419-019-1345-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377709PMC
February 2019
2 Reads
5.014 Impact Factor

Unexpected Prolonged Survival After Extended and Emergent Resection of Pancreatic Metastases from Renal Cell Carcinoma.

J Gastrointest Cancer 2019 Feb 15. Epub 2019 Feb 15.

Policlinico Umberto I, University "La Sapienza", Rome, Italy.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12029-019-00209-w
Publisher Site
http://dx.doi.org/10.1007/s12029-019-00209-wDOI Listing
February 2019
2 Reads

[Ⅳ. Current Economic Issues in Treatment for Metastatic Renal Cell Carcinoma].

Gan To Kagaku Ryoho 2019 Jan;46(1):50-53

Dept. of Urology, Keio University, School of Medicine.

View Article

Download full-text PDF

Source
January 2019
1 Read

[Ⅲ. HowWill the Appearance of New Immunotherapeutic Drugs Change the Treatment against Metastatic Renal Cell Carcinoma ?]

Authors:
Nobuo Shinohara

Gan To Kagaku Ryoho 2019 Jan;46(1):45-49

Dept. of Renal and Genitourinary Surgery, Hokkaido University Graduate School of Medicine.

View Article

Download full-text PDF

Source
January 2019
1 Read

[Ⅱ. How Has the Treatment Outcomes for Advanced Renal Cell Carcinoma Improved in the 10 Years after Approval of Targeted Therapy ?]

Gan To Kagaku Ryoho 2019 Jan;46(1):40-44

Dept. of Urology, Graduate School of Medical Sciences, Kyushu University.

View Article

Download full-text PDF

Source
January 2019
1 Read

[Ⅰ. Are There Any Changes in the Epidemiological Trends in Renal Cell Carcinoma in Japan ?]

Authors:
Hideaki Miyake

Gan To Kagaku Ryoho 2019 Jan;46(1):36-39

Dept. of Urology, Hamamatsu University School of Medicine.

View Article

Download full-text PDF

Source
January 2019
1 Read

Detection of circulating tumour cells and their potential use as a biomarker for advanced renal cell carcinoma.

Can Urol Assoc J 2019 Jan 21. Epub 2019 Jan 21.

Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Introduction: The aim of this study was to detect circulating tumour cells (CTCs) in patients with advanced renal cell carcinoma (RCC) using a novel CTC detection platform. Furthermore, we evaluated the clinical outcomes associated with a CTC-positive status.

Methods: A total of 34 patients with advanced RCC (stage III or IV) were prospectively enrolled, and 104 peripheral blood samples were analyzed for the presence of CTCs at various time points. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5489/cuaj.5605DOI Listing
January 2019
3 Reads

Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome-Associated Renal Cell Carcinoma Showing High FDG Uptake.

Clin Nucl Med 2019 Feb 8. Epub 2019 Feb 8.

Department of Pathology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome is a rare autosomal-dominant disease, characterized by the development of cutaneous and uterine leiomyomas and renal cell carcinoma (RCC). Approximately 20% to 30% of patients with HLRCC syndrome develop RCC resembling sporadic type 2 papillary RCC, which is aggressive and associated with a poor prognosis. Information on the clinical usefulness of FDG PET/CT in HLRCC syndrome-associated RCC is limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002495DOI Listing
February 2019
1 Read

18F-FDG PET/CT Demonstrates Renal Cell Cancer in a Transplant With Synchronous Intestinal Infection.

Clin Nucl Med 2019 Feb 8. Epub 2019 Feb 8.

From the Departments of Nuclear Medicine and PET/CT, and.

We present a case of a 22-year-old man with history of allogenic renal transplantation on immunosuppression, who underwent F-FDG-PET/CT to characterize a lesion in the transplanted kidney on ultrasonogram and contrast-enhanced computed tomography imaging. PET/CT revealed FDG avid lesion in the transplanted kidney and mural thickening involving the distal ileum, ileocecal junction, and ileocolic lymph nodes. Subsequent histopathological examination from the renal lesion revealed renal cell carcinoma in the transplanted kidney. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002482DOI Listing
February 2019
1 Read

Local recurrence of sinonasal renal cell-like adenocarcinoma: A CARE compliant case report.

Medicine (Baltimore) 2019 Feb;98(7):e14533

Department of Pathology.

Rationale: Sinonasal renal cell-like adenocarcinoma (SNRCLA) is a very rare sino-nasal carcinoma. Because SNRCLA has the same morphological features as other clear cell carcinomas, and some of them also occurred in sinonasal part, it is necessary to differentiate SNRCLA from these tumors.

Patient Concerns: A 42-year-old man presented with complaints of epistaxis for 1 day. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014533DOI Listing
February 2019
1 Read

The association between human papillomavirus infection and head and neck cancer: A population-based cohort study.

Medicine (Baltimore) 2019 Feb;98(7):e14436

School of Medicine, Chung Shan Medical University.

Human papillomavirus (HPV) has been linked with development of oropharyngeal squamous cell carcinoma, a subset of head and neck cancer (HNC). This study aimed to evaluate the association between HPV infection and subsequent development of HNC and to report epidemiological information in Taiwan.This population-based cohort study retrieved patient data from the longitudinal health insurance database (LHID) of Taiwan's National Health Insurance Research Database (NHIRD) from 2005 to 2010 and analyzed it retrospectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014436DOI Listing
February 2019
1 Read

Volume Computed Tomography Perfusion Imaging: Evaluation of the Significance in Oncologic Follow-up of Metastasizing Renal Cell Carcinoma in the Early Period of Targeted Therapy - Preliminary Results.

J Comput Assist Tomogr 2019 Feb 11. Epub 2019 Feb 11.

Department of Radiology, and.

Introduction: The aim of this study was to assess the significance of volume computed tomography perfusion imaging of metastasizing renal cell carcinoma (mRCC) in the early period after the initiation of targeted therapy.

Methods: Blood flow (BF), blood volume, and clearance (CL) were calculated in 10 patients with histologically verified mRCC before and 1 month after initiation of targeted therapy using compartmental analysis algorithms. In addition, the longest diameter of tumor was measured for both time points and compared. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RCT.0000000000000848DOI Listing
February 2019
1 Read

[Nephron-sparing surgery for renal tumors].

Urologiia 2018 Oct(4):142-146

Republican Hospital , Yakutsk, Russia.

This review article presents the data on the epidemiology of renal cell carcinoma and describes minimally invasive surgery for this disease. The authors discuss the use of warm and cold ischemia, vascular microdissection, and artery embolization in renal tumor surgery, and analyze treatment outcomes. Read More

View Article

Download full-text PDF

Source
October 2018
1 Read

The diagnostic accuracy and clinical utility of pediatric renal tumor biopsy: Report of the UK experience in the SIOP UK WT 2001 trial.

Pediatr Blood Cancer 2019 Feb 13:e27627. Epub 2019 Feb 13.

Department of Cellular Pathology, University Hospital of Wales, Cardiff, UK.

Introduction: The International Society of Paediatric Oncology (SIOP) protocols recommend preoperative chemotherapy appropriate for Wilms tumors (WTs) in children with renal tumors aged ≥6 months, reserving biopsy for "atypical" cases. The Children's Cancer and Leukaemia Group (CCLG) joined the SIOP-WT-2001 study but continued the national practice of biopsy at presentation.

Method: Retrospective study of concordance between locally reported renal tumor biopsies and central pathology review nephrectomy diagnoses of children enrolled by CCLG centers in the SIOP-WT-2001 study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.27627DOI Listing
February 2019
2 Reads

Pre-cryoablation Embolization of Renal Tumors: Decreasing Probes and Saving Loads.

Cureus 2018 Dec 3;10(12):e3676. Epub 2018 Dec 3.

Radiology, University of Florida College of Medicine, Jacksonville, USA.

The use of adjuvant pre-ablation embolization for renal tumors has been reported in endophytic, centrally located lesions to reduce the risk of injuring the renal collecting system during subsequent cryoablation. In this technical report, we present another utilization of adjuvant pre-ablation embolization, applied for the purpose of decreasing the number of cryoablation probes needed in the ablation intervention. This novel procedural protocol not only decreases the cost of the procedure, but also preserves more normal renal parenchyma, and decreases the risk of injuries related to probe positioning. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.3676DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367110PMC
December 2018
1 Read